Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Serum Free Light Chain Concentration (>1000mg/dl) at Diagnosis and at Relapse Predicts for Very Poor Prognosis in Multiple Myeloma

Abhishek Chilkulwar, MD, Prerna Mewawalla, MD, Anna Miller, Gina Berteotti, Entezam Sahovic, MD, John Lister, MD

Blood (2016) 128 (22): 5698.

https://doi.org/10.1182/blood.V128.22.5698.5698

Published: 2016

Journal Articles

Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation

Cesar O. Freytes, MD, Juan J. Toro, MD, MSci, Rosa F. Yeh, PharmD, Edward A. Stadtmauer, MD, Voravit Ratanatharathorn, MD, Gorgun Akpek, MD, MHS, Entezam Sahovic, MD, Guido J. Tricot, MD, PhD, Paul J. Shaughnessy, MD, Darrell J. White, MD, Tulio E. Rodriguez, MD, Scott R. Solomon, MD, Louie H. Yu, BS, Shiva Patil, PhD, Yiping Sun, PhD, Elizabeth Armstrong, MS, Agnes Elekes, MD, Kazunobu Kato, MD, PhD, Donna E. Reece, MD, FRCPC

Blood (2011) 118 (21): 4509.

https://doi.org/10.1182/blood.V118.21.4509.4509

Published: 2011

Journal Articles

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia.

Heather L. Benjamin, MD, James M. Rossetti, DO, Aaron J. Lampkin, MSIV, Christie Hilton, DO, Entezam Sahovic, MD, Haifaa Abdulhaq, Richard K. Shadduck, MD, Namratha Vemulapalli, MD, Amanda Hercules, MD, John Lister, MD

Blood (2009) 114 (22): 4164.

https://doi.org/10.1182/blood.V114.22.4164.4164

Published: 2009

Journal Articles

Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML)

Haifaa Abdulhaq, MD, Bushra Haq, MD, James M. Rossetti, DO, Richard K. Shadduck, MD, Entezam Sahovic, MD, Dijana Christianson, DO, John Lister, MD

Blood (2008) 112 (11): 5072.

https://doi.org/10.1182/blood.V112.11.5072.5072

Published: 2008

Journal Articles

Low-Dose Azacitidine for Relapse of MDS/AML after Unrelated Donor Peripheral Blood Stem Cell Transplantation.

James M. Rossetti, DO, Richard K. Shadduck, MD, Chandana Thatikonda, MBBS, Entezam Sahovic, MD, John Lister, MD

Blood (2007) 110 (11): 5034.

https://doi.org/10.1182/blood.V110.11.5034.5034

Published: 2007

Journal Articles

Defective γδ T-Cell Function and Granzyme B Gene Polymorphism in Newly Diagnosed Breast Care Patients. Expansion with Zoledronic Acid Partially Compensates for This Deficiency.

Ameera Gaafar, PhD, Abdulla Al-Sulaiman, Alia Iqniebi, Adher Al-Sayed, MD, Entezam Sahovic, MD, Naeem A. Chaudhri, MD, Fahad Al-Mohareb, MD, Dahish Ajarim, MD, Abdelghani Tbakhi, MD, Kkaled Al-Hussein, PhD, Mahmoud Aljurf, MD

Blood (2006) 108 (11): 3880.

https://doi.org/10.1182/blood.V108.11.3880.3880

Published: 2006

NARROW

Serum Free Light Chain Concentration (>1000mg/dl) at Diagnosis and at Relapse Predicts for Very Poor Prognosis in Multiple Myeloma

Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia.

Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML)

Low-Dose Azacitidine for Relapse of MDS/AML after Unrelated Donor Peripheral Blood Stem Cell Transplantation.

Defective γδ T-Cell Function and Granzyme B Gene Polymorphism in Newly Diagnosed Breast Care Patients. Expansion with Zoledronic Acid Partially Compensates for This Deficiency.

Email alerts

ASH Publications

American Society of Hematology

Serum Free Light Chain Concentration (>1000mg/dl) at Diagnosis and at Relapse Predicts for Very Poor Prognosis in Multiple Myeloma

Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia.

Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML)

Low-Dose Azacitidine for Relapse of MDS/AML after Unrelated Donor Peripheral Blood Stem Cell Transplantation.

Defective γδ T-Cell Function and Granzyme B Gene Polymorphism in Newly Diagnosed Breast Care Patients. Expansion with Zoledronic Acid Partially Compensates for This Deficiency.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only